Searched for
DIABETES MOLECULES
These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...- A new nanotech breakthrough could help heal dangerous wounds antibiotics can’t treatScientists are using nanomaterials to heal stubborn wounds that resist antibiotic treatment through a new era of smart wound care. These li...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Stocks in news: SBI, Titan, Hyundai, BSE, Torrent Pharma, Axis BankIndian markets saw volatile trading on Thursday, closing nearly unchanged despite positive signals. Several companies including SBI, Titan,...
- Bayer to buy Perfuse Therapeutics in up to $2.45 billion dealBayer is set to acquire Perfuse Therapeutics in a deal valued up to $2.45 billion. This strategic move aims to enhance Bayer's eye care tre...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 29%In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Obesity drug market to gain as Indians pop the pill and Chinese bring moreIndia's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...
- Anti-diabetic drug tops India's pharma salesIn a grim reminder of the rise of lifestyle diseases, anti-diabetic molecule has for the first time become the largest-selling formulation ...
- Anti-diabetes Molecules: Connexios inks licence deal with German pharma major Boehringer IngelheimFor Connexios, this sale of its anti-diabetes molecules to Boehringer Ingelheim is the first out-licensing deal by an Indian life-sciences ...
- Diabetes, skin care will hold key for drug makers' growth: Credit SuisseThe market share of a drug company is directly related to the number of fast growing molecules in the company's pipeline, the report said.
- India's diabetes drugs market grew 22% at $700 million in FY12The domestic diabetes drugs market for FY 12 grew 22 per cent at $ 700 million, according to a Credit Suisse report.
- How Dr Reddy's chased diabetes molecule dreamDr Reddy’s pursuit of past 13 years for the type 2 diabetes molecule is in its last lap, with the product entering the final phase of clini...
- Foreign players look at India to develop lower-cost drugsGerman pharma major Boehringer Ingelheim is close to completing its first in-licensing deal with an Indian pharmaceutical company.
- Milestone for GlenmarkGlenmark’s out-licensing deal with the German pharma major, Merck KGaA, for its diabetes molecule, a DPP-IV inhibitor, is an important mile...
- Wanted, MNC alliesNew drug discoveries are the pharmaceutical equivalent of an alchemist’s search for a magic formula to turn base metals into gold.
Load More
